News
Sanofi and Sobi present effective bleeding treatment
Sanofi and Swedish Orphan Biovitrum AB (Sobi) have presented positive results from the XTEND-1 pivotal phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa – also known as BIVV001.